Introduction {#sec0001}
============

Acute transient dyspnea (ATD) with transient severe motion (TSM) is an adverse event described in humans during magnetic resonance imaging (MRI) acquisition shortly after injection of gadolinium contrast agents. Most reactions of this nature occur during the arterial phase of the MRI acquisition and are self-limited and mild with no need for medical intervention. However, cases of ATD as part of severe, systemic reactions in humans do occur [@bib0001]. First described in humans in the United States in 2013 (albeit rare) [@bib0002], [@bib0003], ATD to our knowledge has not been reported in the literature for veterinary subjects. Human patients who experience this side effect have difficulty breathing, and the resulting TSM can cause deterioration of image quality during breath-hold phases of MRI acquisition [@bib0003].

Several studies [@bib0004], [@bib0002] reported non-ATD adverse reactions to gadolinium-based contrast agents, most notably off-label use of gadobenate dimeglumine in dogs [@bib0005] and gadoxetate disodium in humans [@bib0006]. The US Food and Drug Administration package insert for gadoxetate use in humans, indicated for intravenous use in MRI of the liver to detect and characterize lesions with known or suspected focal liver disease, lists adverse reactions such as hypertension, respiratory disorders, vomiting, and nausea [@bib0006]. Anaphylactoid reactions (cardiovascular collapse) have also been described by veterinarians during gadolinium-enhanced MRI [@bib0004]. This case indicates an acquired sensitivity to the agent, which was likely an idiosyncratic reaction that developed after the first exposure to the contrast material.

Case report {#sec0002}
===========

As part of development of an infectious disease model in rhesus macaques (*Macaca mulatta*), 12 subjects underwent abdominal 3 T MRI (Philips Healthcare, Cleveland, OH) with a hepatocyte-specific contrast agent at least monthly to detect involvement of abdominal organs, particularly liver and spleen. The subjects underwent imaging at baseline, day 17, day 28, then every 4 weeks up to 1-year postexposure to infection. During imaging, animals on this study were anesthetized intramuscularly with ketamine (15 mg/kg IM 100 mg/mL) [@bib0007], intubated, and maintained with isoflurane 1%-4% [@bib0008] using a ventilator.

During all except 2 of the monthly timepoints in this study, a single animal (8-year-old female) displayed conspicuous body movement (TSM) during the portovenous phase (70 seconds after start of injection of the standard human dose (0.1 mL/kg body weight) of off-label intravenous gadoxetate disodium) of the dynamic T1-high resolution isotropic volume excitation MRI acquisitions [@bib0006]. The abnormal motion was detected only at the 70-second phase ([Fig. 1](#fig0001){ref-type="fig"}C) during the serial MRI sequences with contrast administration; no motion occurred before contrast administration or during earlier or later phases ([Fig. 1](#fig0001){ref-type="fig"}). Because motion was self-limited and never accompanied by other severe clinical signs or complications, the remaining sequences for each examination were completed as stated in the MRI scan protocol.Fig. 1Axial, dynamic T1-high resolution isotropic volume excitation (THRIVE) MRI images of a female rhesus macaque at 182 days postchallenge with an infectious agent were acquired precontrast (A), 10 seconds (B), 70 seconds (C), 3 minutes (D), and 5 minutes (E) postcontrast with gadoxetate disodium intravenous injection. Severe motion artifact is demonstrated on the 70-second image. The subject also rolled onto the right side (D and E).Fig 1

This motion artifact was seen on all the imaging days except for the baseline and day 86 postexposure. Importantly, the motion was associated with transiently increased respiratory and heart rates that were contemporaneous with the movement. The only other concomitant adverse reaction was vomiting once after gadoxetate injection (day 148 postexposure). Interestingly, on day 86, 0.1 mmol/kg of off-label gadobutrol contrast [@bib0009], another type of gadolinium-based agent, was given instead of gadoxetate, and the motion was not seen ([Fig. 2](#fig0002){ref-type="fig"}). After a pattern was discerned after TSM occurred over several examinations, a diagnosis of repeated acute transient tachypnea (ATT) was made. Imaging findings were consistent with TSM artifact associated with ATD reactions in humans noticed after gadolinium-based intravenous injections [@bib0002]. From observation of animal signs, we labeled the reaction ATT rather than ATD.Fig. 2MRI images taken from approximately monthly scans made from a rhesus macaque, each from the 70-second phase of the axial T1-high resolution isotropic volume excitation (THRIVE) sequence following gadoxetate injection. Scans from all dates (A-H) reveal the transient severe motion artifact except baseline (A), and on day 86 (E) when gadobutrol contrast agent was administered in place of gadoxetate.Fig 2

This animal did not require or receive treatment for any condition related to the episodes, because the transiently increased heart rate, respiratory rate, and motion all resolved at the same time and in a self-limited manner. No short- or long-term clinical sequelae were observed despite the repeated occurrences.

Discussion {#sec0003}
==========

ATD most characteristically occurs with gadoxetate administration according to studies investigating different gadolinium-based contrast agents and their adverse effects [@bib0010], [@bib0011]. The causal association in our case between the gadoxetate administration and TSM was not initially suspected on the early MRI image examinations, and the motion was originally considered related to level of anesthesia or other reaction. After noticing repeated TSM artifacts and rapid respiratory rate that occurred during the 70-second phase, a diagnosis of ATT was made. This case is interesting considering the motion artifact only occurred in this animal and that it did not occur on the baseline scan, but every scan thereafter except day 86 when gadobutrol was administered.

Results from one study in humans found that larger injection volumes of gadoxetate reduced the ability to breath hold during the portovenous phase of the MRI, and that a larger off-label dose significantly increased the incidence of TSM artifact [@bib0011]. The animals in our study were given the usual human dose off-label based on weight, and no publications stated that a dose adjustment would be required in rhesus macaques. Therefore, the normal human dosage administered should not be the cause of the TSM artifact. Because the reactions were rarely severe in this study and in the literature [@bib0004], [@bib0011], we were able to use the agent repeatedly without overt complications.

The ATT reaction described here is likely an idiosyncratic reaction after first exposure to gadoxetate (or any other agent) and has not been reported in the literature for veterinary subjects to our knowledge. Other types of anaphylactoid and non-ATD adverse reactions have been reported in veterinary subjects exposed to gadolinium-based contrast materials. This effect is rare yet will cause deteriorated image quality. Alternative contrast agents or administration methods should be considered if a reaction occurs. Gadoxetate should still be considered safe for use in subjects with prior ATD/ATT when needed. However, repeat imaging, reduced acquisition time, using dosing recommendations, longer administration intervals between dosing, and alternative contrast agents should be considered to avoid or reduce the potential motion artifact when appropriate [@bib0010], [@bib0002].
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